Physician profile
Eric Gavin Feinstein
NPI 1720340136
$6,891.45
in general payments reported to CMS, 2019-2025
23 companies · $1,894 in 2025
The $1,894 reported for 2025 was more than what 88% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,067 · 2020: $462 · 2021: $407 · 2022: $560 · 2023: $1,050 · 2024: $1,452 · 2025: $1,894.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,246 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,246.13 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,851.53 | 2019-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $1,062.65 | 2019-2025 | Vabysmo |
| Astellas Pharma US INC | $914.05 | 2023-2025 | Izervay |
| Abbvie INC. | $583.86 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $466.21 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $424.93 | 2022-2025 | Syfovre |
| Allergan, INC. | $241.64 | 2020-2021 | |
| Coherus Oncology, INC. | $178.71 | 2022-2023 | |
| Harrow Eye, LLC | $154.45 | 2025 | Iheezo, Triesence |
| Cardinal Health 110 LLC | $150.00 | 2024 | |
| Regeneron Pharmaceuticals, INC. | $112.85 | 2020 | |
| Kala Pharmaceuticals, INC. | $109.74 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $100.00 | 2019 | |
| Alcon Vision LLC | $96.07 | 2025 | Precision7 |
| Johnson & Johnson Surgical Vision, INC. | $93.13 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $71.33 | 2019 | |
| Dutch Ophthalmic, USA | $71.01 | 2022 | |
| Alimera Sciences, INC. | $67.42 | 2020-2024 | Yutiq, Iluvien |
| Biogen, INC. | $44.77 | 2022-2023 | |
| Bausch & Lomb Americas INC. | $36.86 | 2024-2025 | Xipere, Visudyne |
| Ani Pharmaceuticals, INC. | $21.04 | 2025 | Iluvien |
| Spark Therapeutics, INC. | $19.80 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Feinstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.